OmniGraf

About Transplant Genomics

Transplant Genomics, founded in 2010 and based in San Diego, develops and commercializes non-invasive molecular diagnostic tests for transplant recipients. Its flagship TruGraf tests use peripheral blood gene expression profiles to monitor graft health, detect subclinical acute rejection, and aid in immunosuppression optimization, aiming to reduce reliance on invasive biopsies. As a commercial-stage diagnostics company under the Eurofins umbrella, it targets the significant unmet need for precise, actionable monitoring in the solid organ transplant market.

Therapeutic Areas